LifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management
Rhea-AI Summary
LifeMD (Nasdaq: LFMD) announced it is now offering Eli Lilly's oral GLP-1 pill Foundayo (orforglipron) through its weight management program via an integration with LillyDirect. The FDA approved Foundayo on April 1, 2026.
Foundayo is available to eligible patients with a starting self-pay price of $149/month, commercial patients may pay as little as $25/month with a Lilly savings card, and Medicare coverage is anticipated July 2026. LifeMD says the addition expands its branded GLP-1 offerings and supports virtual, clinically guided weight-management services.
AI-generated analysis. Not financial advice.
Positive
- FDA approval of Foundayo on April 1, 2026
- Starting self-pay price of $149 per month
- Commercial patients may pay as little as $25 per month
- Medicare coverage anticipated July 2026
Negative
- Availability limited to eligible patients in LifeMD program
- Medicare coverage is anticipated, not yet confirmed
- Foundayo enters an already competitive oral GLP-1 market
News Market Reaction – LFMD
On the day this news was published, LFMD gained 2.06%, reflecting a moderate positive market reaction. Argus tracked a peak move of +6.9% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $163.11M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
LFMD was down 2.02% pre-news while momentum peers were mixed: SLP up 13.86% and MNDR down 4.04%, indicating stock-specific factors rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 31 | GLP-1 partnership | Positive | +0.3% | Launch of Wegovy telehealth subscription program with structured savings for patients. |
| Mar 24 | Preferred dividend | Neutral | +0.5% | Declaration of quarterly cash dividend on 8.875% Series A preferred shares. |
| Mar 16 | CFO appointment | Positive | +17.5% | Appointment of new CFO and leadership expansion with equity inducement grant. |
| Mar 09 | Full-year earnings | Positive | +25.3% | Report of strong 2025 revenue growth, EBITDA expansion, cash balance, and subscribers. |
| Mar 03 | Investor conferences | Neutral | +7.2% | Announcement of participation in March healthcare investor conferences and panels. |
Recent LFMD news has generally coincided with positive next-day moves, especially around earnings and leadership updates.
Over the past months, LifeMD has reported strong growth, with full-year 2025 revenue of $194.1 million and adjusted EBITDA of $15.3 million, alongside expanded weight management offerings and national telehealth reach. Leadership changes, including a new CFO and expanded executive team, were followed by notable positive price reactions. The new Foundayo GLP-1 pill offering fits into this ongoing weight management expansion that recently included a Wegovy subscription program, reinforcing LifeMD’s strategy of broadening access to branded obesity therapies across its virtual care platform.
Market Pulse Summary
This announcement expands LifeMD’s weight management platform by adding Foundayo, a once-daily oral GLP-1 pill approved on April 1, 2026, with self-pay pricing from $149 per month and potential insured costs as low as $25. It builds on earlier Wegovy telehealth initiatives and the company’s broader virtual care growth. Investors may watch subscriber trends, reimbursement uptake ahead of expected Medicare coverage in July 2026, and how this therapy contributes to revenue alongside other GLP-1 offerings.
Key Terms
glp-1 medical
cardiometabolic medical
AI-generated analysis. Not financial advice.
LifeMD expands its weight management program with the addition of Foundayo, offering eligible patients an oral alternative to injectable GLP-1 therapies through LillyDirect®
NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that it is now offering Foundayo™ (orforglipron) to eligible patients through its weight management program. Foundayo, developed by Eli Lilly and Company, is a once daily oral treatment for adults with obesity or overweight with weight-related medical problems.
Foundayo is available to eligible LifeMD patients through the Company’s integration with LillyDirect®, which enables prescriptions to be fulfilled and shipped directly to patients. The starting self-pay price for Foundayo is
“The approval of Foundayo is another landmark moment in the treatment of obesity. Patients have access to a once-daily GLP-1 pill that may fit seamlessly into their lives,” said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. “By working with LillyDirect, we are able to offer eligible patients streamlined access to this therapy at an accessible price point. LifeMD remains dedicated to expanding access to high-quality, affordable weight management care, and the addition of Foundayo to our platform furthers that commitment.”
The addition of Foundayo expands LifeMD’s offerings of branded GLP-1 therapies from both Lilly and Novo Nordisk and reinforces LifeMD’s position as a leading destination for clinically guided weight management care with FDA-approved medications.
"The availability of Foundayo reflects Lilly's continued commitment to advancing clinical innovations for patients," said Laura Steele, Group Vice President of U.S. Cardiometabolic Health at Eli Lilly and Company. "We're committed to expanding access to treatment options through channels that meet patients where they are in their journey."
Foundayo is available to eligible patients through the LifeMD weight management program, which provides comprehensive support including virtual consultations with LifeMD’s dedicated clinical team, access to diagnostic testing, secure messaging through a personalized patient portal, and educational resources on diet and lifestyle changes that are important for sustained weight loss and metabolic health. Eligible patients can learn more and schedule a consultation at LifeMD.com.
About LifeMD, Inc.
LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a U.S.-based patient care center to expand access to high-quality, affordable care. For more information, please visit LifeMD.com.
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Investor Contact
Atul Kavthekar, Chief Financial Officer
ir@lifemd.com
Media Contact
Jessica Friedeman, Chief Business Officer
press@lifemd.com
